Vaccine Engagement Day 2026 has arrived! 🎉

Let’s come together to #CelebrateVaccines by sharing information and enhancing public awareness about vaccines!🌟

Discover how you can participate: vist.ly/4v2vi

The use of NHS data has the potential to transform commercial clinical trials in the UK by making recruitment faster, more efficient, and participation more inclusive.

Read our latest report: “Globally competitive UK-wide data-enabled clinical trials: the time is now www.abpi.org.uk/publications...

Innovation with integrity: Why NHS-industry partnerships matter, and how conflicts of interest are managed Dr Amit Aggarwal discusses the importance of NHS-industry relationships, and the safeguards in place to ensure they always put patients and the NHS first.

NHS–industry partnerships are essential for high-quality healthcare. But they can mean conflicts of interest.

Read our blog that explains the safeguards on this - including our strict Code of Practice & independent regulation.

📖 Read more: www.abpi.org.uk/media/blogs/...

Improving Health, Supporting Economic Growth | (HIRANI) Health Innovation Research Alliance Northern Ireland By Marion Laverty, Head of Public Affairs, Northern Ireland, Association of the British Pharmaceutical Industry (ABPI)

Strengthening Northern Ireland’s health and economy through life sciences leadership. 🧬🔬💊💉

Read our colleague Marion Laverty's piece on the ABPI's work in Northern Ireland for @hiranihealth.bsky.social
hira-ni.com/improving-he...

What is Disclosure UK YouTube video by Association of the British Pharmaceutical Industry

🚨New video: Understanding Disclosure UK

Learn how the pharmaceutical industry’s transparency database works, and how it forms part of wider frameworks for managing conflicts of interest.

Watch below ⬇️
www.youtube.com/watch?v=pT5e...

Innovation with integrity: Why NHS-industry partnerships matter, and how conflicts of interest are managed Dr Amit Aggarwal discusses the importance of NHS-industry relationships, and the safeguards in place to ensure they always put patients and the NHS first.

Partnerships between the NHS and the pharmaceutical industry play an important role in improving patient outcomes.

Dr Amit Aggarwal sets out why these relationships matter and the safeguards to ensure transparency and manage conflicts of interest.

www.abpi.org.uk/media/blogs/...

Innovation with integrity: Why NHS-industry partnerships matter, and how conflicts of interest are managed Dr Amit Aggarwal discusses the importance of NHS-industry relationships, and the safeguards in place to ensure they always put patients and the NHS first.

NEW: Our Medical Director Dr Amit Aggarwal's comment on NHS-industry partnerships and the safeguards in place to manage conflicts of interest.

Companies may also benefit from partnerships, but the priority has to be to put the NHS & patients first.
www.abpi.org.uk/media/blogs/...

Our colleague Brian Duggan spoke at the APPG for Black Health event on increasing diversity in clinical trials @paulettehamiltonmp.bsky.social

Lack of diversity in clinical trials is a huge issue that has real consequences for health.

Read his reflections: abpi.org.uk/media/blogs/...

Inshiya and Nina - Medical Affairs Graduates YouTube video by Association of the British Pharmaceutical Industry

This @careersweek.bsky.social we're showcasing the diverse range of roles within the pharmaceutical industry.

If you’re exploring your next step or curious about what a career in the industry can look like visit our job cases studies: www.abpi.org.uk/careers/job-...

www.youtube.com/watch?v=uaoE...

Equity in rare diseases means equal access to diagnosis, treatment, health and social care, and the opportunity to fully participate in society.

Read the @geneticallianceuk.bsky.social report on this: geneticalliance.org.uk/wp-content/u... #RareDiseaseDay #RareEquity

Alan and Ataxia: Explaining the lived experience of a rare disease Alan Thomas from Wales is a patient advocate for rare diseases and Ataxia in particular. Known as ‘the rare disease warrior’; he founded the charity Ataxia and Me, which now has a global following. He...

For #RareDiseaseDay we’re sharing Alan’s amazing journey with ataxia - he founded Ataxia and Me to raise awareness and connect people around the world. 🌍

Thanks to @geneticallianceuk.bsky.social for championing every voice in the rare disease community. 💪

abpi.org.uk/media/blogs/...

For Emily Reuben, CEO, Duchenne UK, equity in rare disease means removing barriers to children getting new treatments. They call for a children’s health technology assessment pathway with achievable evidence standards. #RareDiseaseDay @geneticallianceuk.bsky.social

www.abpi.org.uk/rare-disease...

In a guest blog for #RareDiseaseDay, Laurence Woollard
reflects on what haemophilia gene therapy teaches us about equity, access & adoption of advanced therapies in the NHS.
@geneticallianceuk.bsky.social @cgtcatapult.bsky.social

Read it here: www.abpi.org.uk/media/blogs/...

Rare Disease Day: Prevention can be the most powerful treatment of all Dan O’Connor reflects on the need for greater investment in prevention, as well as the need for equity, for this year’s Rare Disease Day.

🚨New: Blog from our colleague Dan O'Connor for #RareDiseaseDay: Prevention can be the most powerful treatment of all.

A timely read highlighting why equity & prevention are vital. @geneticallianceuk.bsky.social

🔗 Read more: www.abpi.org.uk/media/blogs/...

#RareDiseaseDay2026 #rarequity

Our colleague Dan O'Connor attended the packed @geneticallianceuk.bsky.social Rare Disease Day event yesterday. 🧑‍🤝‍🧑

Great to see so many people calling for equity for rare diseases.

Download the @geneticallianceuk.bsky.social's advocacy pack 👉http://bit.ly/4rp81yB

#rarequity #RareDiseaseDay

Speedy Anna is now award-winning In 2020, we spoke to Anna Turner and her Mum Jenna from Waringstown, Northern Ireland, to get their perspective on living with hypophosphatasia (HPP). In 2024 we caught up with Jenna again to see how ...

✨Meet Anna! She lives with rare bone condition hypophosphatasia (HPP), but nothing stops her.

On #RareDiseaseDay, we celebrate Anna and every person with a rare disease. @geneticallianceuk.bsky.social

Read her story: www.abpi.org.uk/media/blogs/...

This year’s @geneticallianceuk.bsky.social #RareDiseaseDay focuses on equity and why it matters more than ever.

Chris Walden, CEO of @cancer52org.bsky.social, reflects on what equity means in practice.

Read the full Q&A on the ABPI rare disease hub:
👉https://www.abpi.org.uk/rare-diseases/

The theme of this year's #RareDiseaseDay is equity.

In our Q&A, Rick Thompson, CEO of Beacon: for rare diseases reflects on what equity means for him and his organisation.

Read more at the ABPI's rare disease hub www.abpi.org.uk/rare-diseases/ @rarediseaseday.bsky.social

Many medicines entering clinical trials fail because pre-clinical testing does not accurately predict effects in humans.

A key reason? A gap between some 'pre-clinical models' and industry needs.

A new ABPI/@nc3rs.bsky.social review sets out how to close this gap. abpi.org.uk/publications...

A landscape review of human relevant pre-clinical model development in the UK New report by the Association of the British Pharmaceutical Industry (ABPI) and the NC3Rs examines the UK's capabilities in developing human relevant pre-clinical models for medicine development.

We are delighted to publish a report with @abpi.bsky.social that examines the UK landscape in human relevant in vitro models. It will help inform wider policy, funding and infrastructure requirements to accelerate translation and deliver benefits for pharmaceutical R&D. nc3rs.org.uk/news/landsca...

UK opportunity to accelerate development of new medicines New report shows a coordinated approach needed to so academic discoveries can be taken forward with industry to develop new treatments.

🚨The UK has a major opportunity to accelerate the development of new medicines 🧬

A new report from ABPI & @nc3rs.bsky.social shows how to help pre-clinical models turn potential medicines into real-world treatments.

🧷 www.abpi.org.uk/media/news/2...

Careers in the pharmaceutical industry YouTube video by Association of the British Pharmaceutical Industry

Thinking about a career in the pharmaceutical industry?

It's #NationalApprenticeshipWeek & we are sharing the different routes into the industry, including apprenticeships, & the opportunities they open up.

Take a look: www.abpi.org.uk/careers/job-...

www.youtube.com/watch?v=fxXR...

#NAW2026

Despite continued advances in cancer research, UK patients can access fewer cancer medicines through the NHS than patients in comparable European countries.

Find out more about improving access to cancer medicines:
www.abpi.org.uk/publications...

What drives company decisions on new medicine launches and UK investment? In this piece, David Watson, ABPI Executive Director of Patient Access, discusses the findings of ABPI's 2025 Medicines Impact and Investment Survey, which aims to understand how UK policy conditions ...

What drives company decisions on new medicine launches and UK investment?

The findings of ABPI's 2025 Medicines Impact and Investment Survey track how UK policy conditions influence companies' investment and prioritisation decisions for medicines launches.

www.abpi.org.uk/media/blogs/...

At the moment, NHS patients with blood cancer can only access half of the approved medicines for their condition.

Reviewing how these medicines are valued is a first step to giving UK patients the treatments that could save or prolong their lives.

Learn more: www.ourcommongoal.org.uk/blood-cancer/

New breast cancer treatments can extend patients’ lives, yet some remain unavailable in parts of the UK.

Rethinking the way such medicines are valued and approved is a crucial first step in increasing access to life-extending care for more UK patients.

Find out more: www.ourcommongoal.org.uk

Time to emphasise the economics in health economics Victoria Jordan, ABPI Value and Access Policy Director, discusses the Health Economics of the UK-US Economic Prosperity Deal and the commitment to increase NICE's baseline threshold use, the first cha...

It's time to emphasise the economics in health economics. Victoria Jordan discusses the health economics of the UK-US Economic Prosperity Deal and plans increase NICE's baseline threshold use, the first change since its introduction in the early 2000s. abpi.uksouth01.umbraco.io/media/blogs/...

Alzheimer’s devastates the lives of patients and their families, costing billions in care.

New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access.

Find out more: www.ourcommongoal.org.uk

#ABSWawards
As we prepare for the ABSW Awards 2026, we want to thank the partners whose continued support helps us celebrate excellence in science journalism...


@abpi.bsky.social
Dr Katharine Giles Fund
@royalsociety.org
AlphaGalileo

Want to be an ABSW Awards partner?
Find how👉 zurl.co/gPGgo

Publication of 'A Common Understanding 2025' marked an important milestone for collaborative working in Scotland earlier this year.

It shows how partnership across industry, academia & the NHS can improve patient care & drive innovation.

www.gov.scot/publications...